ライフサイエンスコーパス: thrombocytopenic purpura

1 ings secreted by/anchored to ECs (thrombotic thrombocytopenic purpura).

2 e are many definitions for refractory immune thrombocytopenic purpura.

3 splenectomy in patients with chronic immune thrombocytopenic purpura.

4 n used to treat patients with chronic immune thrombocytopenic purpura.

5 -cleaving metalloprotease, causes thrombotic thrombocytopenic purpura.

6 is and targeting treatment of chronic immune thrombocytopenic purpura.

7 management of pregnant patients with immune thrombocytopenic purpura.

8 ne may not be sufficient to cause thrombotic thrombocytopenic purpura.

9 MTS13 activity in plasma leads to thrombotic thrombocytopenic purpura.

10 the diagnostic approach to childhood immune thrombocytopenic purpura.

11 rategies employed in the treatment of immune thrombocytopenic purpura.

12 er clarify its role in idiopathic thrombotic thrombocytopenic purpura.

13 and in an IFN-gamma-enhanced model of immune thrombocytopenic purpura.

14 be treated for these infections, not immune thrombocytopenic purpura.

15 ective means of treating acquired thrombotic thrombocytopenic purpura.

16 arin-induced thrombocytopenia and autoimmune thrombocytopenic purpura.

17 much platelet adhesion may cause thrombotic thrombocytopenic purpura.

18 refractory and relapsing cases of thrombotic thrombocytopenic purpura.

19 hophysiology differs from that of thrombotic thrombocytopenic purpura.

20 refractory and relapsing acquired thrombotic thrombocytopenic purpura.

21 iciency causes a lethal syndrome, thrombotic thrombocytopenic purpura.

22 ongenital and acquired idiopathic thrombotic thrombocytopenic purpura.

23 gG from a patient with idiopathic thrombotic thrombocytopenic purpura.

24 siology and current management of thrombotic thrombocytopenic purpura.

25 rophic microangiopathic disorder, thrombotic thrombocytopenic purpura.

26 g metalloprotease ADAMTS13 causes thrombotic thrombocytopenic purpura.

27 e illnesses also met criteria for thrombotic thrombocytopenic purpura.

28 large multimers, which may cause thrombotic thrombocytopenic purpura.

29 der clinically indistinguishable from immune thrombocytopenic purpura.

30 days or less before the onset of thrombotic thrombocytopenic purpura.

31 ained after splenectomy for trauma or immune thrombocytopenic purpura.

32 c hypoplasia but not in patients with immune thrombocytopenic purpura.

33 ease occur in patients with acute thrombotic thrombocytopenic purpura.

34 Tpo levels are not elevated in human immune thrombocytopenic purpura.

35 n, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

36 develop a practice guideline for idiopathic thrombocytopenic purpura.

37 Adamts13(-/-) mice in a model of thrombotic thrombocytopenic purpura.

38 odies against ADAMTS13 that cause thrombotic thrombocytopenic purpura.

39 enic target for autoantibodies in thrombotic thrombocytopenic purpura.

40 , a condition only experienced in thrombotic thrombocytopenic purpura.

41 while ADAMTS13 deficiency causes thrombotic thrombocytopenic purpura.

42 sistance, multiple sclerosis, and idiopathic thrombocytopenic purpura.

43 MPO were characteristic for acute thrombotic thrombocytopenic purpura.

44 eatening disorder called acquired thrombotic thrombocytopenic purpura.

45 mbocytopenia in patients with chronic immune thrombocytopenic purpura.

46 r microangiopathies, particularly thrombotic thrombocytopenic purpura.

47 cal hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.

48 plasma metalloprotease, leads to thrombotic thrombocytopenic purpura.

49 ances) in the pathogenesis of chronic immune thrombocytopenic purpura.

50 basis for a common bleeding disorder, immune thrombocytopenic purpura.

51 severe, acute and chronic refractory immune thrombocytopenic purpura.

52 y was hereditary spherocytosis (111), immune thrombocytopenic purpura (36), sickle cell disease (SCD)

53 Thrombotic thrombocytopenic purpura, a clinical syndrome characteri

54 d a molecular distinction between thrombotic thrombocytopenic purpura, a disease characterized by a l

55 uman endothelial cells and causes thrombotic thrombocytopenic purpura, a disease with similarities to

56 insights into the pathophysiology of immune thrombocytopenic purpura, a disorder in which autoantibo

57 Thrombotic thrombocytopenic purpura, a life-threatening multisystem

58 During therapy of thrombotic thrombocytopenic purpura, a subtype of TMAs often associ

59 loned mAbs from two patients with thrombotic thrombocytopenic purpura and a healthy person.

60 on the status of current research in immune thrombocytopenic purpura and a preview of agents in deve

61 Third, studies on thrombotic thrombocytopenic purpura and ADAMTS13-knockout mice sugg

62 tomy occurred in 82% of patients with immune thrombocytopenic purpura and hematocrit level increased

63 microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome,

64 ation between ticlopidine use and thrombotic thrombocytopenic purpura and other adverse effects, clop

65 us to understand pathogenesis of thrombotic thrombocytopenic purpura and other arterial thromboses a

66 ld be an antithrombotic agent for thrombotic thrombocytopenic purpura and other thrombotic conditions

67 f any treatment for patients with idiopathic thrombocytopenic purpura and persistent severe thrombocy

68 ascular occlusion associated with thrombotic thrombocytopenic purpura and sepsis was revealed by the

69 munoglobulin G from patients with thrombotic thrombocytopenic purpura and sequence alignment of the A

70 ceptable for patients with refractory immune thrombocytopenic purpura and severe thrombocytopenia wit

71 ions including arthritis, cancer, thrombotic thrombocytopenic purpura and the Ehlers-Danlos type VIIC

72 alikes and their distinction from thrombotic thrombocytopenic purpura and the hemolytic uremic syndro

73 Mutations from thrombotic thrombocytopenic purpura and von Willebrand disease prov

74 0% of patients diagnosed with primary immune thrombocytopenic purpura, and are not associated with di

75 rlying Helicobacter pylori-associated immune thrombocytopenic purpura, and Ghevaert et al. describe a

76 are no specific tests that define idiopathic thrombocytopenic purpura, and management decisions are o

77 sis, autoimmune hemolytic anemia, thrombotic thrombocytopenic purpura, and others.

78 gnosis between inherited and acquired immune thrombocytopenic purpura as well as clinical practice on

79 orders, such as rheumatoid arthritis, immune thrombocytopenic purpura, autoimmune hemolytic anemia, s

80 us platelet disorders, especially idiopathic thrombocytopenic purpura, before consideration of therap

81 pathy and a possible diagnosis of thrombotic thrombocytopenic purpura between Jan 8, 2004, and Dec 6,

82 be the most important therapy in thrombotic thrombocytopenic purpura, but clinical data for adjuncti

83 gy published a practice guideline for immune thrombocytopenic purpura, but treatment recommendations

84 ypical hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, C3GN, and dense deposit diseas

85 Thrombotic thrombocytopenic purpura can occur after the initiation

86 Deaths have been reported for 2.9% of immune thrombocytopenic purpura cases treated with rituximab, b

87 tient suffers from a rare form of idiopathic thrombocytopenic purpura caused by a GPVI-specific autoa

88 hritis, systemic lupus erythematosus, immune thrombocytopenic purpura, chronic cold agglutinin diseas

89 ma exchange in some patients with thrombotic thrombocytopenic purpura; conversely such deficiency is

90 dying 20 patients with congenital thrombotic thrombocytopenic purpura (cTTP) who cannot cleave VWF mu

91 Patients suffering from acquired thrombotic thrombocytopenic purpura develop autoantibodies directed

92 y findings in 11 patients in whom thrombotic thrombocytopenic purpura developed during or soon after

93 and the pathogenesis of clinical thrombotic thrombocytopenic purpura, especially in relation to ADAM

94 Thrombotic thrombocytopenic purpura exemplifies how von Willebrand

95 s for the diagnosis and management of immune thrombocytopenic purpura focused entirely on primary dis

96 re more than 16 years of age, had idiopathic thrombocytopenic purpura for more than 3 months, had a p

97 lasma from 37 patients with acute thrombotic thrombocytopenic purpura had severe deficiency of von Wi

98 of intravenous Rh immune globulin for immune thrombocytopenic purpura has been reported with an estim

99 The treatment landscape of immune thrombocytopenic purpura has the potential for dramatic

100 the pathophysiology of idiopathic thrombotic thrombocytopenic purpura have provided the rationale for

101 itial management of patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-

102 Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-

103 Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-

104 cy, making their distinction from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome diffi

105 ment the reports of occurrence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome durin

106 Case series of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from

107 greatest risk for development of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome is ne

108 Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome occur

109 Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome was a

110 women with congenital or familial thrombotic thrombocytopenic purpura-hemolytic uremic syndrome who w

111 crease the risk for occurrence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

112 We present a case report of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/

113 ish aHUS from other TMAs, such as thrombotic thrombocytopenic purpura; however, novel bioassays are b

114 is), 6; hemolytic uremic syndrome-thrombotic thrombocytopenic purpura (HUS/TTP), 8; systemic lupus er

115 penic purpura in children and chronic immune thrombocytopenic purpura in adults.

116 or the treatment of acute and chronic immune thrombocytopenic purpura in children and chronic immune

117 unding the diagnosis and treatment of immune thrombocytopenic purpura in children continue to evolve.

118 nd within 2 weeks of the onset of thrombotic thrombocytopenic purpura in most patients.

119 evision of the present guidelines for immune thrombocytopenic purpura in pregnancy based on evidence-

120 ples of plasma from patients with thrombotic thrombocytopenic purpura in remission or in 74 plasma sa

121 S13 deficiency is associated with thrombotic thrombocytopenic purpura, in which life-threatening epis

122 Hematology and British guidelines on immune thrombocytopenic purpura incidence, prevalence, and natu

123 ia, antiphospholipid syndrome and thrombotic thrombocytopenic purpura, include immunosuppression and

124 n patients with acute episodes of thrombotic thrombocytopenic purpura, independent of ADAMTS13 activi

125 cidence of ticlopidine-associated thrombotic thrombocytopenic purpura is 1 per 1600 to 5000 patients

126 Idiopathic thrombocytopenic purpura is a common acquired bleeding d

127 Treatment of chronic refractory idiopathic thrombocytopenic purpura is a dilemma because many patie

128 Thrombotic thrombocytopenic purpura is a potentially fatal disease

129 The diagnosis of immune thrombocytopenic purpura is a process of elimination of

130 Thrombotic thrombocytopenic purpura is a rare complication of thien

131 Thrombotic thrombocytopenic purpura is associated with acquired or

132 The acquired form of thrombotic thrombocytopenic purpura is associated with inhibitory a

133 Thrombotic thrombocytopenic purpura is caused by congenital or acqu

134 e onset of ticlopidine-associated thrombotic thrombocytopenic purpura is difficult to predict, despit

135 ed by thrombotic microangiopathy, thrombotic thrombocytopenic purpura is distinguished by a severe de

136 ing protease activity in acquired thrombotic thrombocytopenic purpura is due to an autoantibody inhib

137 Because the incidence of idiopathic thrombocytopenic purpura is greatest in young women, its

138 If the diagnosis of immune thrombocytopenic purpura is in question due to the prese

139 Refractory immune thrombocytopenic purpura is infrequent in children, but

140 about the incidence and prevalence of immune thrombocytopenic purpura is limited, with nearly all dat

141 l investigation of novel therapies in immune thrombocytopenic purpura is undergoing a revolution that

142 Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platele

143 ction in North American patients with immune thrombocytopenic purpura (ITP) and the effect of H pylor

144 ine if megakaryocytes are targeted by immune thrombocytopenic purpura (ITP) autoantibodies, as are pl

145 treatment for adult patients with idiopathic thrombocytopenic purpura (ITP) for more than 50 years.

146 marrow patient and a patient with Idiopathic Thrombocytopenic Purpura (ITP) for the same platelet con

147 The basis of treatment for immune thrombocytopenic purpura (ITP) has conventionally relied

148 Most patients with chronic immune thrombocytopenic purpura (ITP) have autoantibodies direc

149 Guidelines for management of acute immune thrombocytopenic purpura (ITP) in childhood were publish

150 The pathogenesis of chronic idiopathic thrombocytopenic purpura (ITP) involves antibody-mediate

151 Idiopathic thrombocytopenic purpura (ITP) is a common hematologic d

152 Adult chronic immune thrombocytopenic purpura (ITP) is a common hematologic d

153 Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disease

154 Adult chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder

155 Chronic immune thrombocytopenic purpura (ITP) is characterised by accel

156 Chronic immune thrombocytopenic purpura (ITP) is characterized by low p

157 Immune thrombocytopenic purpura (ITP) is characterized by the p

158 Chronic immune thrombocytopenic purpura (ITP) is manifested by autoanti

159 Idiopathic thrombocytopenic purpura (ITP) is the most common acquir

160 Although idiopathic thrombocytopenic purpura (ITP) is the most common autoim

161 Patients with severe immune thrombocytopenic purpura (ITP) may require an acute incr

162 FcgammaR-dependent cytopenias such as immune thrombocytopenic purpura (ITP) or autoimmune hemolytic a

163 Treatments for immune thrombocytopenic purpura (ITP) providing durable platele

164 somes as a new treatment strategy for immune thrombocytopenic purpura (ITP) through the use of a mous

165 allow adults with recently diagnosed immune thrombocytopenic purpura (ITP) who had failed an initial

166 of immune-related diseases, including immune thrombocytopenic purpura (ITP), autoimmune neuropathies,

167 Indications were idiopathic thrombocytopenic purpura (ITP), hereditary spherocytosis

168 ites in 23 countries with chronic idiopathic thrombocytopenic purpura (ITP), platelet counts less tha

169 destructive disorders, including idiopathic thrombocytopenic purpura (ITP), posttransfusion purpura

170 s, the authors concluded that, in idiopathic thrombocytopenic purpura (ITP), production of platelets

171 ) on March 24, 1995, for treatment of immune thrombocytopenic purpura (ITP).

172 the standard first-line treatment for immune thrombocytopenic purpura (ITP).

173 in platelet kinetics associated with immune thrombocytopenic purpura (ITP).

174 in March 1995 to treat patients with immune thrombocytopenic purpura (ITP).

175 in-induced thrombocytopenia (HIT) and immune thrombocytopenic purpura (ITP).

176 er system was developed in a model of immune thrombocytopenic purpura (ITP).

177 s as well as in >80% of patients with immune thrombocytopenic purpura (ITP).

178 ment of children newly diagnosed with immune thrombocytopenic purpura (ITP).

179 adult patients (n = 137) with classic immune thrombocytopenic purpura (ITP; n = 156) or human immunod

180 ancreas/kidney (SPK)] developed a thrombotic thrombocytopenic purpura-like clinical syndrome.

181 ell-characterized murine model of autoimmune thrombocytopenic purpura, male (NZW x BXSB) F1 mice (W/B

182 eral systemic diseases, including thrombotic thrombocytopenic purpura, manifest much of their patholo

183 A diagnosis of immune thrombocytopenic purpura may be based on an evaluation o

184 ts, hypertension (n = 2) and immune-mediated thrombocytopenic purpura (n = 1), were possibly related

185 = 27), neurotoxicity (n = 9) and thrombotic thrombocytopenic purpura (n = 2).

186 management decisions in suspected thrombotic thrombocytopenic purpura, new evidence supporting the ef

187 of the pathological mechanisms of thrombotic thrombocytopenic purpura not only provide a rationale fo

188 Management of refractory immune thrombocytopenic purpura often requires multiple agents

189 ts and children with acute or chronic immune thrombocytopenic purpura or HIV-related thrombocytopenia

190 sseminated intravascular coagulation, immune thrombocytopenic purpura, or splenic sequestration did n

191 as a second-line treatment of chronic immune thrombocytopenic purpura outside a clinical trial.

192 n plasma from patients with acute thrombotic thrombocytopenic purpura, patients with other diseases,

193 es to be indicated for idiopathic thrombotic thrombocytopenic purpura regardless of ADAMTS13 levels,

194 urring in patients with inherited thrombotic thrombocytopenic purpura, resulted in a significant redu

195 associated with diseases such as thrombotic thrombocytopenic purpura, sepsis, and diabetes among oth

196 f delivery of a pregnant patient with immune thrombocytopenic purpura should be determined based on m

197 oglobulin preparation in treatment of immune thrombocytopenic purpura suggests that other mechanisms

198 receiving alemtuzumab developed late immune thrombocytopenic purpura that remitted with standard the

199 In thrombotic thrombocytopenic purpura, the clinical impact of ADAMTS1

200 d with myelodysplastic syndromes, idiopathic thrombocytopenic purpura, thrombocytopenia due to human

201 rotease predisposes patients with thrombotic thrombocytopenic purpura to platelet thrombosis.

202 Thrombotic thrombocytopenic purpura (TTP) affects 1 in 1600 to 1 in

203 Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic synd

204 Acquired thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic synd

205 ich includes two major disorders: thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic synd

206 Thrombotic thrombocytopenic purpura (TTP) and sporadic hemolytic-ur

207 Thrombotic thrombocytopenic purpura (TTP) and the hemolytic uremic

208 Recovery from acute episodes of thrombotic thrombocytopenic purpura (TTP) appears complete except f

209 leading to idiopathic, autoimmune thrombotic thrombocytopenic purpura (TTP) by identifying naturally

210 The pathophysiology of thrombotic thrombocytopenic purpura (TTP) can be explained by the a

211 haemolytic uraemic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP) during an Escherichia col

212 Thrombotic thrombocytopenic purpura (TTP) has been a mysterious and

213 Thrombotic thrombocytopenic purpura (TTP) in adults is usually caus

214 Thrombotic thrombocytopenic purpura (TTP) is a devastating thrombot

215 Immune-mediated thrombotic thrombocytopenic purpura (TTP) is a life-threatening dis

216 Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening dis

217 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening dis

218 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening ill

219 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening sys

220 Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic dis

221 Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threat

222 Thrombotic thrombocytopenic purpura (TTP) is a rare and often fatal

223 Gemcitabine-associated thrombotic thrombocytopenic purpura (TTP) is a rare complication of

224 Thrombotic thrombocytopenic purpura (TTP) is a syndrome with numero

225 Idiopathic thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangi

226 Acquired thrombotic thrombocytopenic purpura (TTP) is caused by aggregation

227 Acquired thrombotic thrombocytopenic purpura (TTP) is characterized by throm

228 The pathogenesis of thrombotic thrombocytopenic purpura (TTP) is obscure.

229 Thrombotic thrombocytopenic purpura (TTP) is primarily caused by im

230 Thrombotic thrombocytopenic purpura (TTP) is the common name for ad

231 Acquired thrombotic thrombocytopenic purpura (TTP) is the consequence of a s

232 Hereditary thrombotic thrombocytopenic purpura (TTP) may be rare, but it is fo

233 (APS), atypical presentations of thrombotic thrombocytopenic purpura (TTP) or heparin-induced thromb

234 factor (VWF)-cleaving protease implicated in thrombocytopenic purpura (TTP) pathogenesis was identifi

235 c ADAMTS13 activity in congenital thrombotic thrombocytopenic purpura (TTP) patients is constrained b

236 In contrast to thrombotic thrombocytopenic purpura (TTP) patients, no aHUS patient

237 mal plasma, and its deficiency in thrombotic thrombocytopenic purpura (TTP) patients, provides additi

238 Although both aHUS and acquired thrombotic thrombocytopenic purpura (TTP) remain clinical diagnoses

239 Pathogenesis of thrombotic thrombocytopenic purpura (TTP) was a mystery for over ha

240 f plasma ADAMTS13 activity causes thrombotic thrombocytopenic purpura (TTP), a life-threatening syndr

241 key factor in the pathogenesis of thrombotic thrombocytopenic purpura (TTP), a life-threatening throm

242 In thrombotic thrombocytopenic purpura (TTP), a multimeric form of von

243 n effective empiric treatment for thrombotic thrombocytopenic purpura (TTP), but how therapy affects

244 may precipitate acute episodes of thrombotic thrombocytopenic purpura (TTP), but pregnancy outcomes i

245 d to a life-threatening disorder, thrombotic thrombocytopenic purpura (TTP), characterized by platele

246 t advances have demonstrated that thrombotic thrombocytopenic purpura (TTP), characterized by widespr

247 ted with platelet transfusions in thrombotic thrombocytopenic purpura (TTP), heparin-induced thromboc

248 aHUS from other TMAs, especially thrombotic thrombocytopenic purpura (TTP), is difficult due to over

249 immune thrombocytopenia (ITP) and thrombotic thrombocytopenic purpura (TTP), respectively, illuminate

250 molytic-uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), the histories and presen

251 In acquired thrombotic thrombocytopenic purpura (TTP), the persistence of sever

252 stic of idiopathic and HIV-linked thrombotic thrombocytopenic purpura (TTP).

253 ts with thienopyridine-associated thrombotic thrombocytopenic purpura (TTP).

254 ombosis in patients with acquired thrombotic thrombocytopenic purpura (TTP).

255 etalloprotease is associated with thrombotic thrombocytopenic purpura (TTP).

256 activity of the protease, causes thrombotic thrombocytopenic purpura (TTP).

257 ssociated with the development of thrombotic thrombocytopenic purpura (TTP).

258 3) revolutionized our approach to thrombotic thrombocytopenic purpura (TTP).

259 to a potentially fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

260 systemic platelet aggregation in thrombotic thrombocytopenic purpura (TTP).

261 Pregnancy can precipitate thrombotic thrombocytopenic purpura (TTP).

262 iency to complement activation in thrombotic thrombocytopenic purpura (TTP).

263 eatening disorder called acquired thrombotic thrombocytopenic purpura (TTP).

264 molytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP).

265 iency leads to the fatal disorder thrombotic thrombocytopenic purpura (TTP).

266 pts to ameliorate the symptoms of thrombotic thrombocytopenic purpura (TTP).

267 ucial role in the pathogenesis of thrombotic thrombocytopenic purpura (TTP).

268 t life-threatening disease called thrombotic thrombocytopenic purpura (TTP).

269 of this enzyme activity leads to thrombotic thrombocytopenic purpura (TTP).

270 severe deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura (TTP).

271 to a potentially fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

272 d our understanding of idiopathic thrombotic thrombocytopenic purpura (TTP).

273 le in pathogenesis of the disease thrombotic thrombocytopenic purpura (TTP); however, experimental ev

274 TTP cases from the United Kingdom Thrombotic Thrombocytopenic Purpura (UK TTP) Registry with clinical

275 ssociated with the development of thrombotic thrombocytopenic purpura, usually within 1 month of init

276 stances of ticlopidine-associated thrombotic thrombocytopenic purpura were identified.

277 In secondary forms of immune thrombocytopenic purpura, when the hematologist plays a

278 A more common TMA is thrombotic thrombocytopenic purpura, which is caused by the lack of

279 However, patients with chronic idiopathic thrombocytopenic purpura who harbor predominantly young

280 Adults with severe thrombocytopenic purpura who responded poorly to therape

281 itors, and the risk of relapse of thrombotic thrombocytopenic purpura will be important to further va

282 ease platelet counts in patients with immune thrombocytopenic purpura, without significant adverse ef